International intellectual property strategies for therapeutic antibodies
- PMID: 22123063
- PMCID: PMC3242846
- DOI: 10.4161/mabs.3.6.17788
International intellectual property strategies for therapeutic antibodies
Abstract
Therapeutic antibodies need international patent protection as their markets expand to include industrialized and emerging countries. Because international intellectual property strategies are frequently complex and costly, applicants require sound information as a basis for decisions regarding the countries in which to pursue patents. While the most important factor is the size of a given market, other factors should also be considered.
Figures
References
-
- In re Hilmer 359 F.2d 859. (CCPA 1966)
-
- Arts. 6 + 7 of the Argentine Patent Act and Argentine Guidelines for Examination of Patent application, Part C, Chapter IV, 2.1.7.
-
- Decision of the European Court of Justice in case C-34/10 of March 10, 2011. Available from: http://curia.europa.eu.
-
- Association for Molecular Pathology v. United States PTO, 2010 US Dist. LEXIS 35,418. (S.D.N.Y. Apr 2, 2010)
MeSH terms
Substances
LinkOut - more resources
Full Text Sources